In a recent feature for Biospace, journalist Tristan Manalac spoke with Racura chairman Pete Smith about the difficulties in targeting the notoriously undruggable myc gene. Along with RIPK1, STING and alpha-synuclein, myc has left a trail of failed clinical trials, cancelled partnerships and sunk investments in their wake, said Manalac.

Read the full article here.